Sarepta Therapeutics (SRPT) Tops Q4 EPS by 36c
Tweet
Share
E-mail
Get Alerts SRPT Hot Sheet
Join SI Premium – FREE
Sarepta Therapeutics (NASDAQ: SRPT) reported Q4 EPS of $1.90, $0.36 better than the analyst estimate of $1.54. Revenue for the quarter came in at $658.4 million versus the consensus estimate of $589.45 million.
For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AeroVironment restates quarterly financials, citing $89M goodwill error
- KeyBanc: 'Best Buy (BBY) Powering Up for the Next Chapter'; CEO/CFO Meeting Highlights
- Ennis (EBF) Reports In-Line Q1 EPS
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
